HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

C.E.R.A. administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II.

AbstractBACKGROUND AND OBJECTIVE:
C.E.R.A. (continuous erythropoietin receptor activator, pegilated-rHuEPO ß) corrects and maintains stable hemoglobin levels in once-monthly administration in chronic kidney disease (CKD) patients. The aim of this study was to evaluate the management of anemia with C.E.R.A. in CKD patients not on dialysis in the clinical setting.
METHODS:
Two hundred seventy two anemic CKD patients not on dialysis treated with C.E.R.A. were included in this retrospective, observational, multicentric study during 2010. Demographical characteristics, analytical parameters concerning anemia, treatment data and iron status were recorded.
RESULTS:
C.E.R.A. achieved a good control of anemia in both naïve patients (mean Hemoglobin 11.6g/dL) and patients converted from a previous ESA (mean Hemoglobin 11.7g/dL). Most naïve patients received C.E.R.A. once monthly during the correction phase and required a low monthly dose (median dose 75 µg/month). The same median dose was required in patients converted from a previous ESA, and it was lower than recommended in the Summary of Product Characteristics (SPC). Iron status was adequate in 75% of anemic CKD patients, but only 50% of anemic patients with iron deficiency received iron supplementation.
CONCLUSIONS:
C.E.R.A. corrects and maintains stable hemoglobin levels in anemic CKD patients not on dialysis, requiring conversion doses lower than those recommended by the SPC, and achieving target hemoglobin levels with once-monthly dosing frequency both in naïve and converted patients.
AuthorsAlberto Martínez-Castelao, Aleix Cases, Elisabeth Coll, Jordi Bonal, Josep M Galceran, Joan Fort, Francesc Moreso, Vicente Torregrosa, Lluís Guirado, Pilar Ruiz, Investigators of the Micenas II study
JournalNefrologia : publicacion oficial de la Sociedad Espanola Nefrologia (Nefrologia) Vol. 35 Issue 1 Pg. 80-6 ( 2015) ISSN: 1989-2284 [Electronic] Spain
PMID25349927 (Publication Type: Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Hemoglobins
  • continuous erythropoietin receptor activator
  • Erythropoietin
  • Polyethylene Glycols
  • Iron
Topics
  • Adolescent
  • Adult
  • Aged
  • Anemia (etiology, prevention & control)
  • Anemia, Iron-Deficiency (blood, drug therapy, etiology)
  • Diabetic Nephropathies (blood)
  • Drug Administration Schedule
  • Erythropoietin (administration & dosage, therapeutic use)
  • Female
  • Hemoglobins (analysis)
  • Humans
  • Iron (blood)
  • Male
  • Middle Aged
  • Polyethylene Glycols (administration & dosage, therapeutic use)
  • Renal Insufficiency, Chronic (blood, complications)
  • Retrospective Studies
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: